Cargando…

Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization

INTRODUCTION: Hypoglycemia and fear of hypoglycemia may contribute to basal insulin discontinuation, poor glycemic control, and increased healthcare burden in patients with type 2 diabetes (T2D). This study aimed to determine the impact of hypoglycemia soon after basal insulin initiation on treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalal, Mehul R., Kazemi, Mahmood, Ye, Fen, Xie, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599444/ https://www.ncbi.nlm.nih.gov/pubmed/28779282 http://dx.doi.org/10.1007/s12325-017-0592-x

Ejemplares similares

Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States
por: Bajpai, Sanjay, et al.
Publicado: (2021)

Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
por: Boronat, Mauro, et al.
Publicado: (2015)

Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes
por: Roussel, Ronan, et al.
Publicado: (2020)

Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk: Executive Summary
por: Anderson, John, et al.
Publicado: (2020)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
por: Reynolds, Shannon L., et al.
Publicado: (2017)

Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
por: Kalirai, Samaneh, et al.
Publicado: (2020)

Factors and outcomes associated with discontinuation of basal insulin therapy in patients with type 2 diabetes mellitus
por: Zhang, Puhong, et al.
Publicado: (2020)

The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin
por: Aleppo, Grazia, et al.
Publicado: (2021)

Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Clinical and Cost Implications of Insulin Degludec in Patients with Type 1 Diabetes and Problematic Hypoglycemia: A Quality Improvement Project
por: Karamat, Muhammad Ali, et al.
Publicado: (2018)

Effects of inadequate coverage on healthcare utilization: A regression discontinuity analysis
por: Dugan, Jerome A., et al.
Publicado: (2021)

Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England
por: McEwan, Philip, et al.
Publicado: (2015)

Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis
por: Karpes Matusevich, Aliza R, et al.
Publicado: (2021)

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
por: Johansen, Odd Erik, et al.
Publicado: (2009)

Predictive Modeling of Hypoglycemia Risk with Basal Insulin Use in Type 2 Diabetes: Use of Machine Learning in the LIGHTNING Study
por: Bosnyak, Zsolt, et al.
Publicado: (2019)

A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study
por: Nishimura, Akiko, et al.
Publicado: (2017)

The importance of the initial period of basal insulin titration in people with diabetes
por: Khunti, Kamlesh, et al.
Publicado: (2020)

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia: Reduction in nocturnal hypoglycemia in those at greatest risk
por: Choudhary, Pratik, et al.
Publicado: (2011)

Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
por: Huang, Wan-Chun, et al.
Publicado: (2021)

Healthcare utilization and costs of cardiopulmonary complications following cardiac surgery in the United States
por: Stevens, Mitali, et al.
Publicado: (2019)

Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
por: Elsaid, Mohamed I., et al.
Publicado: (2020)

Healthcare resource utilization and costs among children with cystic fibrosis in the United States
por: Thorat, Teja, et al.
Publicado: (2021)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Importance of Insulin Immunoassays in the Diagnosis of Factitious Hypoglycemia
por: Nalbantoğlu Elmas, Özlem, et al.
Publicado: (2014)

The Economic Burden of Insulin-Related Hypoglycemia in Spain
por: Parekh, Witesh, et al.
Publicado: (2017)

Paliperidone Induced Hypoglycemia by Increasing Insulin Secretion
por: Omi, Tsubasa, et al.
Publicado: (2016)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

All-Cause Health Care Utilization and Costs Associated with Newly Diagnosed Multiple Sclerosis in the United States
por: Asche, Carl V., et al.
Publicado: (2010)

The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System
por: Parekh, Witesh, et al.
Publicado: (2018)

Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes
por: Groener, Jan Benedikt, et al.
Publicado: (2019)

Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States
por: Khorana, Alok A, et al.
Publicado: (2013)

Effect of Naloxon on Counter Insulin Hormone Secretion in Insulin-Induced Hypoglycemia
por: Ju, Yeong Shil, et al.
Publicado: (1987)

Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog
por: Su, Chih-Ting, et al.
Publicado: (2016)

Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008–2014
por: Tong, Sabine, et al.
Publicado: (2018)

Healthcare resource utilization and cost among patients with type 1 diabetes in the United States
por: Simeone, Jason C, et al.
Publicado: (2020)

534. Healthcare Resource Utilization and Costs among Patients with COVID-19 in the United States
por: Liu, Gui, et al.
Publicado: (2023)

Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
por: Kobayashi, Monica, et al.
Publicado: (2023)

Bilateral Basal Ganglia Lesions in a Dialytic Patient with Diabetes and Recurrent Hypoglycemia
por: Jung, Jong Hwan
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j0d40g29gne7127oaouluujcpg